Thurston Springer Miller Herd & Titak’s Direxion Daily S&P Biotech Bull 3X ETF LABU Stock Holding History

Thurston Springer Miller Herd & Titak’s Portfolio LABU Stock Details LABU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-230	Closed	-$36.7K	–	1388
2025 Q4	$36.7K	Sell	230 -276	-55%	-$37.9K	0.01%	572
2025 Q3	$47.4K	Buy	506 +206	+69%	+$14.6K	0.09%	208
2025 Q2	$17.1K	Buy	+300	New	+$15.9K	﹤0.01%	995
2024 Q4	–	Sell	-337	Closed	-$43.4K	–	1368
2024 Q3	$43.4K	Buy	+337	New	+$44K	0.01%	594

Other funds holding LABU

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Jump Financial Chicago, Illinois $7.5B AUM 33.9% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

MIG

McGuire Investment Group Wakefield, Rhode Island $885M AUM 47.78% 1-Year Est. Return

Belvedere Trading Chicago, Illinois $84.4B AUM 52.68% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Thurston Springer Miller Herd & Titak's LABU Position: Q1 2026 in Review

Thurston Springer Miller Herd & Titak sold out of Direxion Daily S&P Biotech Bull 3X ETF (LABU) in Q1 2026, closing a stake of 230 shares — an estimated $36.7K sold.

Thurston Springer Miller Herd & Titak first reported a position in LABU in Q3 2024 and held it in 4 quarters. The position peaked at $47.4K in Q3 2025. 33 funds tracked by Wall St. Rank hold LABU as of Q1 2026.

Thurston Springer Miller Herd & Titak reported no remaining Direxion Daily S&P Biotech Bull 3X ETF position as of Q1 2026 after selling out during the quarter.
Thurston Springer Miller Herd & Titak sold 230 Direxion Daily S&P Biotech Bull 3X ETF shares in Q1 2026, an estimated $36.7K.
Thurston Springer Miller Herd & Titak first reported a position in Direxion Daily S&P Biotech Bull 3X ETF in Q3 2024 and held it in 4 quarters.
Thurston Springer Miller Herd & Titak's Direxion Daily S&P Biotech Bull 3X ETF position peaked at $47.4K in Q3 2025.
33 funds tracked by Wall St. Rank held Direxion Daily S&P Biotech Bull 3X ETF as of Q1 2026.

Based on Thurston Springer Miller Herd & Titak's 13F filing for Q1 2026, filed 14 Apr 2026.